Monitoring of Antiplatelet Therapy

  • Udaya S. Tantry
  • Aung Myat
  • Paul A. GurbelEmail author


The variability of response to antiplatelet agents and its potential relation to the occurrence of recurrent ischemic events have stimulated the concept of antiplatelet therapy monitoring over the last decade. This has been driven further by the development of user-friendly point-of-care methods to assess platelet reactivity to adenosine diphosphate. Large observational studies have established an independent relation between the results of point-of-care platelet function testing and adverse clinical outcomes, particularly in patients undergoing coronary artery stenting. Furthermore, the concept of a “therapeutic window” for P2Y12 receptor reactivity has been proposed, with an upper threshold associated with ischemic events and a lower threshold associated with bleeding. Prospective randomized trials have, however, failed to demonstrate that tailored antiplatelet therapy based on point-of-care assessment of platelet function is effective in reducing ischemic event occurrences. In the absence of robust prospective evidence to support a personalized approach, decisions regarding antiplatelet therapy rest on patient comorbidity, the large body of observational data, national and international guidelines, and recognition of the fundamental importance of platelet physiology in causing catastrophic events in those with high-risk coronary artery disease.


Percutaneous Coronary Intervention Antiplatelet Therapy Stent Thrombosis P2Y12 Receptor Platelet Reactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aradi D, Storey RF, Komócsi A et al (2014) Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 35:209–215CrossRefPubMedGoogle Scholar
  2. Bliden KP, DiChiara J, Tantry US et al (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49:657–666CrossRefPubMedGoogle Scholar
  3. Bonaca MP, Bhatt DL, Steg PG et al (2016) Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 37(14):1133–1142CrossRefPubMedGoogle Scholar
  4. Bonello L, Camoin-Jau L, Arques S et al (2008) Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51:1404–1411CrossRefPubMedGoogle Scholar
  5. Bonello L, Camoin-Jau L, Armero S et al (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103:5–10CrossRefPubMedGoogle Scholar
  6. Bonello L, Tantry US, Marcucci R et al (2010) Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933CrossRefPubMedGoogle Scholar
  7. Bonello L, Mancini J, Pansieri M et al (2012) Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 10:1999–2005CrossRefPubMedGoogle Scholar
  8. Born GV (1965) Platelets in thrombogenesis: mechanism and inhibition of platelet aggregation. Ann R Coll Surg Engl 36:200–206PubMedPubMedCentralGoogle Scholar
  9. Campo G, Fileti L, de Cesare N et al (2010) 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 56:1447–1455CrossRefPubMedGoogle Scholar
  10. Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474–2483CrossRefPubMedGoogle Scholar
  11. Chen WH, Cheng X, Lee PY et al (2007) Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120:631–635CrossRefPubMedGoogle Scholar
  12. Collet JP, Cuisset T, Rangé G et al (2012) ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109CrossRefPubMedGoogle Scholar
  13. Cuisset T, Frere C, Quilici J et al (2008) Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 1:649–653CrossRefPubMedGoogle Scholar
  14. De Caterina R, Marchioli R, Andreotti F (2013) Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 368:871PubMedGoogle Scholar
  15. Eikelboom JW, Hirsh J, Weitz JI (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650–1655CrossRefPubMedGoogle Scholar
  16. Eikelboom JW, Hankey GJ, Thom J (2008) Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118:1705–1712CrossRefPubMedGoogle Scholar
  17. Ferraris VA, Saha SP, Oestreich JH et al (2012) Society of Thoracic Surgeons. Society of Thoracic Surgeons. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 94:1761–1781CrossRefPubMedGoogle Scholar
  18. Fontana P, Berdagué P, Castelli C et al (2010) Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 8:2614–2623CrossRefPubMedGoogle Scholar
  19. Geisler T, Grass D, Bigalke B et al (2008) The Residual Platelet Aggregation After Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6:54–61CrossRefPubMedGoogle Scholar
  20. Gum PA, Kottke-Marchant K et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961–965CrossRefPubMedGoogle Scholar
  21. Gurbel PA, Tantry US (2010) Combination antithrombotic therapies. Circulation 121:569–583CrossRefPubMedGoogle Scholar
  22. Gurbel PA, Tantry US (2011) An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 305:1136–1137CrossRefPubMedGoogle Scholar
  23. Gurbel PA, Tantry US (2012) Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 125:1276–1287CrossRefPubMedGoogle Scholar
  24. Gurbel PA, Tantry US (2016) Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. Eur Heart J 37(14):1143–1144CrossRefPubMedGoogle Scholar
  25. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908–2913CrossRefPubMedGoogle Scholar
  26. Gurbel PA, Bliden KP, Hayes KM, Tantry U (2004) Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2:535–545CrossRefPubMedGoogle Scholar
  27. Gurbel PA, Bliden KP, Guyer K et al (2005a) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING Study. J Am Coll Cardiol 46:1820–1826CrossRefPubMedGoogle Scholar
  28. Gurbel PA, Bliden KP, Samara W et al (2005b) The clopidogrel resistance and stent thrombosis (CREST) study. J Am Coll Cardiol 46:1827–1832CrossRefPubMedGoogle Scholar
  29. Gurbel PA, Bliden KP, DiChiara J et al (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115:3156–3164CrossRefPubMedGoogle Scholar
  30. Gurbel PA, Bliden KP, Navickas IA et al (2010) Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 160:346–354CrossRefPubMedPubMedCentralGoogle Scholar
  31. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Committee for Practice Guidelines. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999–3054CrossRefPubMedGoogle Scholar
  32. Hirsh PD, Hillis LD, Campbell WB et al (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304:685–691CrossRefPubMedGoogle Scholar
  33. Jneid H, Anderson JL, Wright RS et al (2012) ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60:645–681CrossRefPubMedGoogle Scholar
  34. Kirtane A (2013) New insights into high platelet reactivity and the existence of a therapeutic window: ADAPT-DES at 2 years. Presented at TCT 2013. Accessed 24 Jan 2014
  35. Levine GN, Bates ER, Blankenship JC et al (2011) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124:e574–e651CrossRefPubMedGoogle Scholar
  36. Mahla E, Suarez TA, Bliden KP et al (2012) Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 5:261–269CrossRefPubMedGoogle Scholar
  37. Mauri L, Kereiakes DJ, Yeh RW et al (2014) DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166CrossRefPubMedPubMedCentralGoogle Scholar
  38. Michelson AD, Cattaneo M, Eikelboom JW (2005) Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3:1309–1311CrossRefPubMedGoogle Scholar
  39. Price MJ, Berger PB, Teirstein PS et al (2011) GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105CrossRefPubMedGoogle Scholar
  40. Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315CrossRefPubMedGoogle Scholar
  41. Sibbing D, Schulz S, Braun S et al (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250–256CrossRefPubMedGoogle Scholar
  42. Stone GW, Witzenbichler B, Weisz G et al (2013) ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623CrossRefPubMedGoogle Scholar
  43. Tantry US, Bliden KP, Gurbel PA (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46:1705–1709CrossRefPubMedGoogle Scholar
  44. Tantry US, Mahla E, Gurbel PA (2009) Aspirin resistance. Prog Cardiovasc Dis 52:141–152CrossRefPubMedGoogle Scholar
  45. Tantry US, Bonello L, Aradi D et al (2013) Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62:2261–2273CrossRefPubMedGoogle Scholar
  46. Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159–2164CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Inova Center for Thrombosis Research and Drug DevelopmentInova Heart and Vascular InstituteFairfaxUSA
  2. 2.King’s College London BHF Centre of Research Excellence, The Rayne Institute, Cardiovascular DivisionSt. Thomas’ HospitalLondonUK

Personalised recommendations